Advertisement
Home »

Immune Checkpoint Inhibition Improves Outcomes in Non-BRCA Variant Ovarian Cancer

Jun 12, 2023

REFERENCES & ADDITIONAL READING

DiSilvestro P, et al. J Clin Oncol. 2023;41:609-617.

Bannerjee S, et al. Ann Oncol. 2022;33(suppl_7):S235-S282.

Harter P, et al. Durvalumab with paclitaxel/carbo[platin and bevacizumab followed by maintenance durvalumab, bevacizumab and Olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/BRACA2 mutation: results from the randomized, placebo-controlled phase III DUO-O/ENGOT-ov46/AGO-OVAR 23/GOG-3025 trial. Abstract LBA5506. ASCO Annual Meeting 2023, 2–6 June, Chicago.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement